Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "prognostic marker" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-7 z 7
    Tytuł:
    K-ras gene mutation as an early prognostic marker of colon cancer
    Autorzy:
    Szpon, Łukasz
    Stal, Aleksander
    Zawadzki, Marcin
    Lis-Nawara, Anna
    Kielan, Wojciech
    Grzebieniak, Zugmunt
    Kelan, Wojciech
    Grzebiak, Zygmunt
    Powiązania:
    https://bibliotekanauki.pl/articles/1394055.pdf
    Data publikacji:
    2016
    Wydawca:
    Index Copernicus International
    Tematy:
    K-ras gene mutation
    colorectal cancer
    Opis:
    Due to increased colorectal cancer incidence there is a necessity of seeking new both prognostic and prediction factors that will allow to evolve new diagnostic tests. K-ras gene seems to be such a factor and its mutations are considered to be an early marker of progression of colorectal cancer. The aim of the study was to find a correlation between K-ras gene mutation in patients with diagnosed colorectal cancer and selected clinical parameters. Material and methods. A total of 104 patients (41 women and 63 men) with diagnosed colorectal cancer were included in this study. The average age of male group was 68.3 and in female group – 65.9. Samples were taken from paraffine blocks with tissue from diagnosed patients and K-ras gene mutation were identified. Afterwards the statistical analysis was made seeking the correlation betweenK-ras gene mutation incidence and clinical TNM staging system, tumour localisation, histological type, sex, age. Results. K-ras gene mutations were detected in 20.1% of all colorectal cancers. Significantly higher rate of K-ras gene mutations were diagnosed among patients classified at stage I (40%), stage IIC (50%) and stage IV (50%) according to the TNM classification. Conclusions. The results of our study are compatible with other studies and indicate the correlation between K-ras gene mutation and colorectal cancer incidence. Identification of K-ras gene mutation may complement other diagnostic methods at early stage of colorectal cancer.
    Źródło:
    Polish Journal of Surgery; 2016, 88, 1; 15-19
    0032-373X
    2299-2847
    Pojawia się w:
    Polish Journal of Surgery
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Is the Monocyte/HDL Ratio a Prognostic Marker of Idiopathic Sudden Hearing Loss?
    Autorzy:
    Koçak, Hasan Emre
    Acipayam, Harun
    Elbistanlı, Mustafa Suphi
    Yiğider, Ayşe Pelin
    Alakhras, Wesam
    Kıral, Mehmet Nurettin
    Kayhan, Fatma Tülin
    Powiązania:
    https://bibliotekanauki.pl/articles/1398598.pdf
    Data publikacji:
    2016
    Wydawca:
    Index Copernicus International
    Tematy:
    hearing loss
    HDL
    Monocyte
    Ratio
    Opis:
    Objective: In this study, our aim was to investigate whether Monocyte/HDL ratio is a marker of the prognosis of the idiopathic sudden hearing loss (ISHL). Study design: Retrospective, case-control clinical trial. Materials and Methods: 45 patients, who were diagnosed with idiopathic sudden hearing loss and were treated with the same therapy regime and 47 healthy volunteers, who applied to the hospital for routine controls and had audiological and laboratory examination between March 2014 and December 2015, were included in the study. Monocyte/HDL ratios of the patients in the study and control groups were calculated from the results of the blood counts and biochemical analysis. Additionally, the study group was divided into two sub-groups regarding their responses (responders and non-responders) to the treatment determined by the audiological examination, which was carried out after 3 months according to the Siegel criteria. The Monocyte/HDL ratios between the groups were statistically evaluated. Results: There was no statistically significant difference between the MHRs of the study and control groups (p=0.574). However, the MHR was significantly higher in the non-responders’ group compared with the responders’ group, although they were treated with the same therapy regimen (p=0.005). Conclusion: There was no difference in MHRs between study and control groups. However, as MHR was higher in the patients with good prognosis compared with the patients with bad prognosis, we believe that regarding the ISHL, MHR is not a predictive value but might have prognostic marker.
    Źródło:
    Polish Journal of Otolaryngology; 2016, 70, 5; 26-30
    0030-6657
    2300-8423
    Pojawia się w:
    Polish Journal of Otolaryngology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    TIMP-2 potencjalnym markerem prognostycznym w guzach pochodzenia neuroblastycznego
    TIMP-2 a potential prognostic marker in neuroblastoma group of tumors
    Autorzy:
    Taran, Katarzyna
    Owecka, Agata
    Lewandowska, Małgorzata
    Kobos, Józef
    Powiązania:
    https://bibliotekanauki.pl/articles/552948.pdf
    Data publikacji:
    2014
    Wydawca:
    Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
    Tematy:
    TIMP-2
    neuroblastoma
    prognoza
    Źródło:
    Family Medicine & Primary Care Review; 2014, 2; 175-177
    1734-3402
    Pojawia się w:
    Family Medicine & Primary Care Review
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer.
    Autorzy:
    Smolarz, Beata
    Romanowicz-Makowska, Hanna
    Kulig, Andrzej
    Powiązania:
    https://bibliotekanauki.pl/articles/1043627.pdf
    Data publikacji:
    2003
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    PCR
    1334G/A polymorphism
    prognostic marker
    colorectal cancer
    plasminogen activator inhibitor 1 (PAI-1)
    Opis:
    Plasminogen activator inhibitor 1 (PAI-1) content in colorectal cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumours predict poor prognosis. The gene encoding PAI-1 is highly polymorphic and PAI-1 gene variability could contribute to the level of PAI-1 biosynthesis. In the present work the distribution of genotypes and frequency of alleles of the 1334G/A polymorphism in 92 subjects with colorectal cancer in samples of cancer tissue and distant mucosa samples as well as in blood were investigated. Blood samples age matched healthy individuals (n = 110) served as control. The 1334G/A polymorphism was determined by PCR amplification using allele specific primers. No differences in the genotype distributions and allele frequencies between blood, distant mucosa samples and cancer tissue were detected. However, the distribution of the genotypes of the 1334G/A polymorphism in patients differed significantly (P <0.05) from those predicted by the Hardy-Weinberg equilibrium. There were significant differences in the frequencies of alleles between the colorectal cancer subjects and controls (P <0.05). The results support the hypothesis that the 1334G/A polymorphism may be associated with the incidence of colorectal cancer.
    Źródło:
    Acta Biochimica Polonica; 2003, 50, 2; 489-495
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
    Autorzy:
    Błasiak, Janusz
    Smolarz, Beata
    Powiązania:
    https://bibliotekanauki.pl/articles/1044431.pdf
    Data publikacji:
    2000
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    gene polymorphism
    PAI-1 gene
    prognostic marker
    plasminogen activator inhibitor-1 (PAI-1)
    breast cancer
    Opis:
    The antigen content of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis for patients. The gene encoding PAI-1 is highly polymorphic and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in subjects with breast cancer were investigated. Tumor tissues were obtained from 100 postmenopausal women with node-negative and node-positive ductal breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The 4G/5G polymorphism was determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 4G/5G polymorphism in both control and patients did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between node-positive and node-negative patients. The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.
    Źródło:
    Acta Biochimica Polonica; 2000, 47, 1; 191-199
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Lymphovascular space invasion, a prognostic marker for disease recurrence in patients with early endometrioid endometrial cancer
    Inwazja przestrzeni limfatycznej jako wskaźnik prognostyczny wznowy uchorych naendometrioidalnego raka trzonu macicy we wczesnym stopniu zaawansowania
    Autorzy:
    Hyun Lee, Seung
    Park, Jung-Woo
    Han, Myeongsuk
    Powiązania:
    https://bibliotekanauki.pl/articles/1029680.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Communications
    Tematy:
    endometrial cancer
    lymphovascular space invasion
    recurrence
    Opis:
    Aim of the study: To evaluate the clinicopathologic factors of early International Federation of Gynecology and Obstetrics (FIGO) stage I–II endometrioid endometrial cancer in a single institution and to emphasize factors contributing to recurrence. Material and methods: We selected several clinicopathologic factors including age, height, body weight, body mass index, cancer antigen-125, FIGO tumor grade, myometrial invasion, lymphovascular space invasion, estrogen receptor/ progesterone receptor status, and adjuvant radiation therapy or systemic chemotherapy. Univariate and multivariate Cox proportional hazard model and Kaplan–Meier estimates were used for analyzing all clinicopathologic factors related to the risk of disease recurrence. Results: The median age was 55.05 years, and the median follow-up time was 35 months. Eleven patients (11%) showed disease recurrence, 3 patients – distant, and 8 patients – local metastasis. In univariate analysis, tumor grade (P = 0.0045) and lymphovascular space invasion (P = 0.0374) were associated with disease recurrence. Multivariate analysis demonstrated an association between any type of recurrence and lymphovascular space invasion (hazard ratio, HR, 6.308; 95% confidence interval, CI 1.851–11.484). Conclusions: Our study showed that the presence of lymphovascular space invasion is an important factor for disease recurrence in early endometrial cancer. Therefore, adjuvant systemic chemotherapy may be considered in patients with early endometrial cancer with lymphovascular space invasion.
    Celem pracy była ocena kliniczno-patologicznych cech endometrioidalnego raka błony śluzowej trzonu macicy w stadium I–II według klasyfikacji Międzynarodowej Federacji Ginekologii i Położnictwa (International Federation of Gynecology and Obstetrics, FIGO) w jednym ośrodku oraz podkreślenie czynników wpływających na wznowę choroby. Materiał i metody: W pracy wybrano kilka kliniczno-patologicznych czynników, takich jak wiek, wzrost, masa ciała, wskaźnik masy ciała, wartość antygenu nowotworowego CA-125, stopień w klasyfikacji FIGO, inwazja myometrium, inwazja przestrzeni limfatycznej, status receptorów estrogenowych/progesteronowych, a także radioterapia lub chemioterapia adiuwantowa. W celu oceny wszystkich cech kliniczno-patologicznych związanych z ryzykiem nawrotu choroby zastosowano jednoi wieloczynnikowy model proporcjonalnego ryzyka Coxa oraz analizę metodą Kaplana–Meiera. Wyniki: Mediana wieku wynosiła 55,05 roku, a mediana czasu obserwacji – 35 miesięcy. Nawrót choroby odnotowano u 11 chorych (11%): przerzuty odległe w 3, a wznowę miejscową w 8 przypadkach. W analizie jednoczynnikowej z nawrotem choroby powiązane były stopień złośliwości guza (P = 0,0045) oraz inwazja przestrzeni limfatycznej (P = 0,0374). Analiza wieloczynnikowa wykazała związek między każdym rodzajem nawrotu a inwazją przestrzeni limfatycznej (współczynnik ryzyka – hazard ratio, HR, 6,308; 95% przedział ufności CI 1,851–11,484). Wnioski: Wyniki niniejszego badania wskazują, że obecność inwazji przestrzeni limfatycznej jest ważnym czynnikiem nawrotu wczesnego raka endometrium. Można zatem rozważyć zastosowanie adiuwantowej chemioterapii u chorych na raka endometrium we wczesnym stopniu zaawansowania z inwazją przestrzeni limfatycznej.
    Źródło:
    Current Gynecologic Oncology; 2017, 15, 3; 183-188
    2451-0750
    Pojawia się w:
    Current Gynecologic Oncology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Carcinoembryonic antigen as a tumor marker in lung cancer – is it clinically useful?
    Autorzy:
    Okuła, Agnieszka
    Karczmarek-Borowska, Bożenna
    Powiązania:
    https://bibliotekanauki.pl/articles/454789.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    carcinoembryonic antigen
    lung cancer
    prognostic factor
    tumor marker
    Opis:
    Introduction. Lung cancer is the most common cancer in the Western world. Annually there are approximately 1.8 million new cases worldwide. It is characterized by poor prognosis with a 5-year survival of 10-17% depending on the country. Contributing to this poor prognosis is a mainly late diagnosis, as well as a fairly frequent recurrence despite radical surgery. Over the years, scientists have been searching for a tumor marker that would be useful for patients with lung cancer. Aim. The aim of this study is to discuss the significance of carcinoembryonic antigen (CEA) in the diagnosis, prognosis of the disease course, and monitoring patients with lung cancer. Methods. Review of the literature using the PubMed database, Termedia, Via Medica and the key issue: carcinoembryonic antigen as a tumor marker in lung cancer. Conclusions. Serum CEA level can be a reliable complement to the diagnosis of lung cancer. It can be helpful in preoperative prediction of disease course and qualification for adjuvant treatment of non-small cell lung cancer especially adenocarcinoma. Trends and normalization of CEA during chemotherapy have an impact on progression-free survival and overall survival (OS) of patients. Various available publications describe CEA as a marker for metastatic lung cancer, which is the most specific for metastasis in the liver and brain.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2018, 1; 53-59
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-7 z 7

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies